Shigellosis
3
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
GSKLONDON, United Kingdom
3 programs2
1
Tebipenem PivoxilPhase 21 trial
S. sonnei 1790GAHBPhase 11 trial
S. sonnei 1790GAHBPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
GSKTebipenem Pivoxil
GSKS. sonnei 1790GAHB
GSKS. sonnei 1790GAHB
Clinical Trials (3)
Total enrollment: 234 patients across 3 trials
Tebipenem Trial in Children With Shigellosis
Start: Aug 2022Est. completion: Aug 2026132 patients
Phase 2Active Not Recruiting
Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults
Start: Mar 2014Est. completion: Apr 201552 patients
Phase 1Completed
A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.
Start: Feb 2014Est. completion: Mar 201550 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space